Pharmaceutical industry – Page 27
-
BusinessCelgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
BusinessFDA new drug approvals more than doubled in 2017
The FDA approved 46 new drugs last year – the highest number in over two decades – due to factors like streamlined policies at the agency
-
Research1500 reactions per day go with the flow
Automated flow chemistry system puts high-speed spin on drug discovery
-
BusinessNon-profit generic drug company created
Intermountain Healthcare is leading an effort in the US to prevent drug shortages and end their skyrocketing prices
-
NewsUK drug discovery model must ‘break and change’
Report calls for joined-up approach that brings together charities, industry and universities
-
BusinessDementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies
-
NewsThe latest lethal injection row explained
Two US states plan to use untried drugs to execute prisoners
-
BusinessTeva to cut 14,000 jobs
Saddled with debt in an increasingly competitive generic drug industry, the Israel-headquartered giant begins a difficult transformation
-
OpinionFor the sake of argument
It’s important to recognise which disputes can actually be resolved by science
-
ResearchSuzuki–Miyaura–hydrogenation targets 3D drugs
Researchers design a new pathway to make sp3 enriched drug molecules
-
BusinessPharmaceuticals roundup 2017
Political influence has strongly shaped industry activity in the past year
-
BusinessBayer and J&J lose first blood thinner lawsuit
US jury fines Xarelto makers $27.8 million for downplaying drug risks
-
BusinessMerck & Co and Qiagen to build UK research hubs
Almost 2000 jobs to be created at research centres in Manchester and London
-
BusinessEuropean drug regulator heads to Amsterdam
Brexit drives EMA to relocate, taking hundreds of jobs and significant expertise away from UK
-
OpinionBeyond buckets and batches
Embracing flow chemistry means leaving behind some faithful friends
-
BusinessTargeting rare diseases
Is working on genetic mutations that affect only a few in every thousand people risky?
-
BusinessBayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
FeatureStaying one step ahead of the game
Clare Sansom examines the need for agile drug development when tackling emerging viral disease outbreaks
-
BusinessChina clamps down on polluting factories
Thousands of factories face closure or sanctions as authorities exercise new powers to curb air and water pollution
-
BusinessChuck Norris versus gadolinium
US action star is suing 11 drug firms for $10m, claiming his wife was poisoned by gadolinium from her MRIs